Second Warning Letter Directed At Boston Scientific’s Chemotherapy Ports
This article was originally published in The Gray Sheet
Executive Summary
FDA cites Boston Scientific for quality system regulation violations related to the firm's valved Vaxcel chest ports and catheters in an Aug. 1 1warning letter